CoChat
Sign Up
Cited by 279Statistical Methods in Clinical TrialsMeta-analysis and systematic reviewsMusculoskeletal pain and rehabilitation

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

Open access
Moore, R A, Moore, O A, Derry, S, Peloso, P M, Gammaitoni, A R, Wang, H·2010·Annals of the Rheumatic Diseases
DOI 10.1136/ard.2009.107805PMC PMC2800200
Open this paper in CoChat — free accountOpen PDF

Abstract

Though long-term exposure to nicotine is highly addictive, one "beneficial" consequence of chronic tobacco use is a reduced risk for Parkinson9s disease. Interestingly, these effects both reflect structural and functional plasticity of brain circuits controlling reward and motor behavior, and specifically recruitment of nicotinic acetylcholine receptors (nAChR) in mesencephalic dopaminergic neurons. Since the underlying cellular mechanisms are poorly understood, we addressed this issue employing primary cultures of mouse mesencephalic dopaminergic neurons. Exposure to nicotine (1-10 μM) for 72 hr in vitro increased dendritic arborization and soma size in primary cultures. These effects were blocked by mecamylamine and dihydro-β-erythroidine, but not methyllycaconitine. The involvement of α4β2 nAChR was supported by the lack of nicotine-induced structural remodeling in neurons from α4 null mutant mice (KO). Challenge with nicotine triggered phosphorylation of the extracellular signal-regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt) followed by activation of the mTORC1-dependent p70 ribosomal S6 protein kinase. Upstream pathway blockade using the phosphatidylinositol 3-kinase inhibitor LY294002 resulted in suppression of nicotine-induced phosphorylations and structural plasticity. These effects were dependent upon functional DA D3 receptor (D3R) since nicotine was inactive both in cultures from D3R KO mice and following pharmacologic blockade with D3R antagonist SB-277011-A (50 nM). Finally, exposure to nicotine in utero (5 mg/kg/day for 5 days) resulted in increased soma area of DAergic neurons of newborn mice, effects not observed in D3KO mice. These findings indicate that nicotine-induced structural plasticity in mesencephalic dopaminergic neurons involves α4β2 nAChRs together with dopamine D3R-mediated recruitment of ERK/Akt-mTORC1 signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard.2009.107805

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Percentage of responders over baseline at various levels of reductions in pain intensity (PR) for placebo and five active drugs over 12 weeks of treatment.
Figure 1 Percentage of responders over baseline at various levels of reductions in pain intensity (PR) for placebo and five active drugs over 12 weeks of treatment.CC BY · PubMed Central
Figure 2 Numbers needed to treat (NNT) compared with placebo for five active drugs over 12 weeks of treatment using various levels of reductions in pain intensity (PR) over baseline.
Figure 2 Numbers needed to treat (NNT) compared with placebo for five active drugs over 12 weeks of treatment using various levels of reductions in pain intensity (PR) over baseline.CC BY · PubMed Central
Figure 3 Weighted mean difference between treatment and flare/randomisation visit for WOMAC pain subscale: active treatment minus placebo. Shading shows upper and lower 95% confidence intervals.
Figure 3 Weighted mean difference between treatment and flare/randomisation visit for WOMAC pain subscale: active treatment minus placebo. Shading shows upper and lower 95% confidence intervals.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Moore, R. A., Moore, O. A., Derry, S., Peloso, P. M., Gammaitoni, A. R., & Wang, H.
Affiliations
  • John Radcliffe Hospital (GB)
  • Musgrave Park Hospital (GB)
  • University of Oxford (GB)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
  • Moore, R A
  • Moore, O A
ORCID
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2010-02
Volume
69
Issue
2
Pages
374-379
ISSN
0003-4967 (ISSN-L)
DOI
10.1136/ard.2009.107805
PMC
PMC2800200
OpenAlex
W2103600429
Cited by
279
References
38
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 2 · 2022: 9 · 2021: 5 · 2020: 4 · 2019: 14 · 2018: 13 · 2017: 38 · 2016: 27 · 2015: 31 · 2014: 25 · 2013: 32 · 2012: 16
FWCI
2.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Oxford University Research Archive (ORA) (University of Oxford) (acceptedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Pfizer
  • AstraZeneca
  • National Institute for Health and Care Research
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
Keywords
etoricoxib, osteoarthritis, analgesia, number needed to treat, responder analysis, nicotine, Parkinson's disease risk, nicotinic acetylcholine receptors, alpha4beta2 nAChR, midbrain dopaminergic neurons, dendritic branching, dopamine D3 receptor
MeSH terms
Etoricoxib, Diffusion of Innovation, Dose-Response Relationship, Drug, Humans, Pain, Pain Measurement, Pyridines, Sulfones, Osteoarthritis, Hip, Randomized Controlled Trials as Topic, Treatment Outcome, Osteoarthritis, Knee, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review